Who are CRx-197's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Qutenza Patch, Capsaicin Topical Cream, SafeTynadol®, Cannabidiol Oral Product, Capsaicin 8%, MediCabilis CBD Oil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/crx-197.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

CRx-197 — Competitive Intelligence Brief

CRx-197 (CRx-197) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TRPV1 receptor modulator. Area: Pain.

phase 2 TRPV1 receptor modulator TRPV1 Pain Small molecule Live · refreshed every 30 min

Target snapshot

CRx-197 (CRx-197) — Zalicus. CRx-197 is a small molecule that modulates the TRPV1 receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CRx-197 TARGET	CRx-197	Zalicus	phase 2	TRPV1 receptor modulator	TRPV1
Qutenza Patch	Qutenza Patch	M.D. Anderson Cancer Center	marketed	Topical analgesic; TRPV1 agonist	TRPV1 (transient receptor potential vanilloid 1)
Capsaicin Topical Cream	Capsaicin Topical Cream	Women and Infants Hospital of Rhode Island	marketed	Topical analgesic; TRPV1 agonist	TRPV1 (transient receptor potential vanilloid 1)
SafeTynadol®	SafeTynadol®	Sinew Pharma Inc.	marketed	Analgesic/antipyretic (acetaminophen derivative)	Presumed COX inhibitor and TRPV1 modulator (acetaminophen mechanism)
Cannabidiol Oral Product	Cannabidiol Oral Product	University of Connecticut	marketed	Cannabinoid	Multiple targets including CB1/CB2 (allosteric modulation), 5-HT1A receptor, TRPV1 channel
Capsaicin 8%	Capsaicin 8%	Averitas Pharma, Inc.	marketed	Topical analgesic; TRPV1 agonist	TRPV1 (transient receptor potential vanilloid 1)
MediCabilis CBD Oil	MediCabilis CBD Oil	Gold Coast Hospital and Health Service	marketed	Cannabinoid	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor (multiple targets)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TRPV1 receptor modulator class)

Zalicus · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CRx-197 — Competitive Intelligence Brief. https://druglandscape.com/ci/crx-197. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab